TERIFLUNOMIDE AGH, TERIFLUNOMIDE ALEMBIC, TERILEX, TERIFLUNOMIDE APPL, TERIFLUNOMIDE APL, TERILEMBIC TERIFLUNOMIDE, TERIBIC, TERIFLUNOMIDE APGH, TERIFLUNOMIDE ALEM, TERIFLUNOMIDE APEL, TERIFLUNOMIDE APAL, TERIFLUGIO, TERIFLUNOMIDE AGL, TERIFLUNOMIDE AGHL,
Product name
TERIFLUNOMIDE AGH, TERIFLUNOMIDE ALEMBIC, TERILEX, TERIFLUNOMIDE APPL, TERIFLUNOMIDE APL, TERILEMBIC TERIFLUNOMIDE, TERIBIC, TERIFLUNOMIDE APGH, TERIFLUNOMIDE ALEM, TERIFLUNOMIDE APEL, TERIFLUNOMIDE APAL, TERIFLUGIO, TERIFLUNOMIDE AGL, TERIFLUNOMIDE AGHL, TERIFLUNOMIDE APA, TERIMIDE
Date registered
Evaluation commenced
Decision date
Approval time
161 working days (255)
Active ingredients
teriflunomide
Registration type
New generic medicine
Indication
TERIFLUNOMIDE AGH, TERIFLUNOMIDE ALEMBIC, TERILEX, TERIFLUNOMIDE APPL, TERIFLUNOMIDE APL, TERILEMBIC TERIFLUNOMIDE, TERIBIC, TERIFLUNOMIDE APGH, TERIFLUNOMIDE ALEM, TERIFLUNOMIDE APEL, TERIFLUNOMIDE APAL, TERIFLUGIO, TERIFLUNOMIDE AGL, TERIFLUNOMIDE AGHL, TERIFLUNOMIDE APA, TERIMIDE (film-coated tablets) are indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine